Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1K24AT009893-01 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Children's Healthcare of Atlanta | OTHER |
| National Center for Complementary and Integrative Health (NCCIH) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.
Arginine is a simple amino acid that is found in many foods and is part of the proteins in a human's body. Patients with sickle cell disease have low levels of the amino acid arginine and these low levels may be related to pain episodes. Increasing levels of arginine in the blood may lower pain and/or lower the amount of pain medication (like morphine) that is needed to treated them. It may also decrease the amount of time spent in the hospital.
Available data suggest that, L-arginine is a safe & efficacious intervention with narcotic-sparing effects in pediatric SCD patients with VOE. The addition of a higher loading dose to the standard dose or use of a continuous infusion may provide additional clinical benefits by overcoming multiple mechanisms that limit global arginine bioavailability in SCD.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard dose | Experimental | Subjects with sickle cell disease (SCD) and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first |
|
| Loading dose + standard dose | Experimental | Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive an intravenous (IV) infusion of a standard dose of arginine (100 mg/kg) three times a day for seven days or until discharged from the hospital, whichever occurs first |
|
| Loading dose + continuous infusion | Experimental | Subjects with sickle cell disease and vaso-occlusive painful events (VOE) will be randomized to receive an intravenous (IV) infusion of an initial loading dose of arginine (200 mg/kg) given over 30 minutes and then receive a continuous intravenous (IV) infusion of 300 mg/kg/24hr for 7 days or until discharged from the hospital, whichever occurs first |
|
| Non-Randomized Loading dose 500 mg/kg + standard dose | Experimental | Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) arginine dose at 500 mg/kg once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Arginine | Drug | Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge.
|
| Measure | Description | Time Frame |
|---|---|---|
| Pharmacokinetics of IV arginine, measured by plasma arginine concentration over time | Total time plasma arginine levels are maintained above the half-saturating concentration (Km) of cationic amino acid transporter protein-1 (CAT-1), which is 150 µM (normal range of extracellular plasma arginine concentration). pK samples will be collected at 6 time-points within 8 hours: prior to arginine treatment (time 0), and at 60, 90, 120 minutes, 4 and 8 hours after the initiation of arginine therapy, and then every 24 hours up to 7 days. | Day 1 through study completion, an average of up to 7 days |
| Change in nitric oxide metabolites | The formation of NO metabolites will be measured by determination of its stable end products in serum; nitrite (NO2-) and nitrate (NO3-). Change in nitric oxide metabolites will be calculated as the difference in metabolites from the time prior to arginine treatment (baseline) to the end of the intervention period. | Baseline, day 1 through study completion, an average of up to 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| Area Under the Plasma Concentration -Time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration for Arginine | AUC is derived from drug concentration and time so it gives a measure of how much and how long a drug stays in a body. AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]) | Day 1 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Reshika Mendis, MBBS | Contact | 404-785-4525 | Reshika.mendis@choa.org | |
| Claudia Morris, MD | Contact | 404 727-5500 | claudia.r.morris@emory.edu |
| Name | Affiliation | Role |
|---|---|---|
| Claudia Morris, MD | Emory University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Children's Healthcare fo Atlanta at Hughes Spalding | Recruiting | Atlanta | Georgia | 30303 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32384147 | Result | Morris CR, Brown LAS, Reynolds M, Dampier CD, Lane PA, Watt A, Kumari P, Harris F, Manoranjithan S, Mendis RD, Figueroa J, Shiva S. Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso-occlusive pain. Blood. 2020 Sep 17;136(12):1402-1406. doi: 10.1182/blood.2019003672. | |
| 38527291 | Result | Korman R, Hatabah D, Brown LA, Harris F, Wilkinson H, Rees CA, Bakshi N, Archer DR, Dampier C, Morris CR. Impact of arginine therapy on kyotorphin in children with sickle cell disease and vaso-occlusive pain. Blood Adv. 2024 Jun 25;8(12):3267-3271. doi: 10.1182/bloodadvances.2023012209. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000755 | Anemia, Sickle Cell |
| ID | Term |
|---|---|
| D000745 | Anemia, Hemolytic, Congenital |
| D000743 | Anemia, Hemolytic |
| D000740 | Anemia |
| D006402 | Hematologic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D001120 | Arginine |
| ID | Term |
|---|---|
| D024361 | Amino Acids, Basic |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
| D000599 | Amino Acids, Diamino |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Non-Randomized Loading dose 300 mg/kg + standard dose | Experimental | Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) arginine dose at 300 mg/kg once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first. |
|
| Non-Randomized Loading dose 400mg/kg + standard dose | Experimental | Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) arginine dose at 400 mg/kg once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first. |
|
|
| Arginine (Loading) | Drug | Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) at each specified group dose once, followed by a standard dose of 100mg/kg every 8 hours until discharge or for a total of 21 doses of arginine, whichever comes first. |
|
|
| Arginine (Continuous) | Drug | Arginine will be dispensed intravenously (in the vein) as a continuous IV infusion of 300 mg/kg/24hr |
|
|
| Maximum observed plasma concentration of arginine | Maximum measured concentration of the arginine in plasma | Day 1 |
| Apparent clearance of arginine | The clearance of a drug measures the rate at which the drug is removed from the body after the dose. Clearance of arginine after intravenous administration on day 1. | Day 1 |
| Terminal elimination half-life (t1/2) for arginine | Terminal phase elimination half-life (t1/2) is the time required for half of the drug to be eliminated from the plasma. | Day 1 |
| Change in red blood cell (RBC) arginine | Change in rbc arginine will be calculated as rbc arginine at the end of arginine administration minus rbc arginine at baseline. | Baseline, day 1 through study completion, an average of up to 7 days |
| Daily urine arginine | Total amount of arginine excreted in urine daily | From Day 1 until study completion, an average of up to 7 days |
| Global arginine bioavailability (GABR) | GABR represents a measure of endothelial function. GABR will be calculated by arginine divided by the sum of ornithine plus citrulline [arginine/(ornithine+citrulline)]. | From enrollment through study completion, an average of up to 7 days |
| Change in asymmetric dimethylarginine (ADMA) levels | ADMA is is a metabolic by-product of continual protein modification processes and interferes with L-arginine in the production of nitric oxide. Change in ADMA levels will be calculated as ADMA levels at the end of arginine administration minus ADMA levels at baseline. | Baseline, day 1 and through study completion, an average of up to 7 days |
| Modeling nitric oxide (NOx) level versus plasma arginine level | Modeling nitric oxide (NOx) level versus plasma arginine level will be measured. | From enrollment through study completion, an average of up to 7 days |
| Biomarkers of hemolysis | Biomarkers of hemolysis (lactate dehydrogenase, hemoglobin, reticulocytes, arginase, indirect bilirubin) represent intravascular hemolysis and nitric oxide bioavailability. | From enrollment through study completion, an average of up to 7 days |
| Erythrocyte glutathione levels | Erythrocyte glutathione is a biomarker for oxidative stress. It will be measured by using liquid chromatography. | From enrollment through study completion, an average of up to 7 days |
| Level of cytokines | Cytokines are biomarkers for inflammation. Cell supernatants will be collected and analyzed for different cytokines. | From enrollment through study completion, an average of up to 7 days |
| Children's Healthcare of Atlanta at Arthur M. Blank Hospital | Recruiting | Atlanta | Georgia | 30329 | United States |
|
| D006425 |
| Hemic and Lymphatic Diseases |
| D006453 | Hemoglobinopathies |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D000601 | Amino Acids, Essential |